13 Nov Treatment for SARS-CoV-2 with REGN-COV2 monoclonal antibodies in adult outpatients
The REGN 2067 study is testing an infusion of REGN-COV2, a combination of two antibodies against SARS-CoV-2, the virus that causes COVID-19, to see whether they can: decrease the amount of virus in the body; decrease the length of time the virus is in the body; and decrease the length and severity of COVID-19 illness.
This study is being conducted at Fred Hutch’s COVID-19 Clinical Research Center in Seattle, WA (as one of the study’s site locations) and will enroll pregnant women who have recently tested positive for SARS-CoV-2 and are symptomatic. The study is an adaptive, phase 1/2/3, randomized, double-blind, placebo-controlled master protocol. The pregnant women cohort enrolled will all receive active product, no placebo. The antibodies in this study cannot give you SARS-CoV-2.
If you qualify and decide to join the clinical treatment study, you will be compensated for your time. Transportation to the CCRC for appointments is also available, at no charge to the participant, and can be discussed at the time of screening. The Study Team will not share participant’s private health information or citizenship information at any point, Social Security information is not needed, and Health Insurance is not needed and is not charged.
– Adults 18 years of age or older at the time of signing the informed consent
– Currently Pregnant – will all receive active product, no placebo.
– Laboratory confirmed SARS-CoV-2 infection, with test results within past 72 hours of enrollment
– Symptomatic – experiencing at least one of the symptoms common of COVID-19
– Able to attend all appointments at the Fred Hutch CCRC in Seattle, WA within the study schedule. Vehicular transportation to the CCRC for appointments is also available, at no charge to the participant, and can be discussed at the time of screening with the study team.
COVID-19 Clinical Research Center Team
Additional Study Details
Full Study Title
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19
Dr. Michael Boeckh, Fred Hutch
Dr. Shelly Karuna, Fred Hutch
Accepts Healthy Volunteers?
Fred Hutch COVID-19 Clinical Research Center
820 Minor Ave N. Entrance B
Seattle, Washington 98109